APR 20, 2016 09:22 AM PDT

New 'Game Changer' Drug for Head and Neck Cancer

WRITTEN BY: Xuan Pham

Immunotherapy, the technique of using the immune system to fight off disease, is one of the most promising avenues for anticancer treatments. And this route seems to be paying off, as researchers announced a new immune drug that’s more effective than traditional chemotherapy against aggressive head and neck cancers.

Image credit: Pixabay.com

The drug is called nivolumab, and belongs to a class of medicines called PD-1 immune checkpoint inhibitors. Essentially this drug works by blocking a programmed death receptor in the body’s immune cells, allowing these cells to perk up longer and attack the tumor. The drug is marketed under the name Opdivo by Bristol-Myers Squibb, and is FDA-approved for the treatment of other cancer types, including melanoma, lung and kidney cancer.
 
"We don't have effective treatments for advanced head and neck cancers - these cancers are notoriously difficult to treat. So it's exciting that this phase III trial has been the first to show a significant survival benefit with an immunotherapy," said Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, and the senior study author. "Once it has relapsed or spread, head and neck cancer is extremely difficult to treat, with surgery and radiotherapy often impossible. So it's very good news for patients that these interim results indicate we now have a new treatment that works, and can significantly extend life."
 
In a phase III clinical trial, researchers compared nivolumab in 240 head and neck cancer patients versus 121 patients who were given the traditional chemotherapy. The team found, within one year, patient survival rate for nivolumab (36 percent) was more than doubled that of standard chemotherapy (17 percent). The results from this trial, called Checkmate-141, were reported in the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
 
"Nivolumab was not only more effective than chemotherapy for patients with head and neck cancer but also had fewer side-effects, and has the potential to significantly extend life and increase quality of life,” Harrington added. They reported side effects were seen in about 13 percent of patients on nivolumab, whereas over 35 percent of patients on standard chemotherapy had side effects.
 
Because its effectiveness was so apparent, the clinical trial ended early and patients on standard chemo treatments were given the option to switch to nivolumab.
 
“We are encouraged by the overall survival results seen with this investigational use of nivolumab versus three standards of care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who often face poor survival rates. These findings are supportive of our Immuno-Oncology research goal to study potential treatment options for their ability to help patients with difficult-to-treat cancers achieve long-term survival,” said Jean Viallet, Global Clinical Research Lead, Oncology, Bristol-Myers Squibb.
 


Additional sources: MNT, BBC

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 01, 2018
Health & Medicine
JUN 01, 2018
Research Shows The Cause of Childhood Leukemia
Babies and young children need to be kept safe by the adults in their lives, however keeping them in a germ-free environment might not be the best idea. Ch...
JUL 24, 2018
Cancer
JUL 24, 2018
FDA Approves New Drug for Refractory/Relapsed AML
A new drug and new drug class have been approved by the FDA for relapsed or refractory AML patients with an IDH1 mutation. The new drug offers options for patients....
AUG 21, 2018
Cancer
AUG 21, 2018
Theranostics.....Heard of it?
Theranostics is an emerging field that combines therapeutics and diagnostic capabilities into one opportunity for treatment of diseases, especially cancer....
SEP 02, 2018
Cell & Molecular Biology
SEP 02, 2018
Cancer Cell Lines can Evolve in the Lab
New research shows that scientists have to take steps to verify the identity of the cell lines they grow....
SEP 15, 2018
Cancer
SEP 15, 2018
Undescended testicles could lead to testicular cancer and infertility in adult males
An undescended testis (cryptorchidism) is a condition in which one of the testes or both have not descended into the right position in the scrotum at birth and either stay at the abdomen or d...
OCT 04, 2018
Videos
OCT 04, 2018
Zebrafish as Metastatic Cancer Model
Another Koch Institute Image Award winner from 2018 is presented in this video from MIT....
Loading Comments...